Evidence map›Paper›PMID 39828608›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Polymeric Anti-Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution.

Roya Koshani, Shang-Lin Yeh, Zeming He, Naveen Narasimhalu, Landon G Vom Steeg, Derek G Sim, Robert J Woods, Andrew F Read, Amir Sheikhi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Roya KoshaniDepartment of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA.ORCID 0000-0001-9849-3963
Shang-Lin YehDepartment of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA.
Zeming HeDepartment of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA.
Naveen NarasimhaluDepartment of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA.
Landon G Vom SteegDepartment of Biology and Entomology, The Pennsylvania State University, University Park, PA, 16802, USA.
Derek G SimDepartment of Biology and Entomology, The Pennsylvania State University, University Park, PA, 16802, USA.
Robert J WoodsDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
Andrew F ReadDepartment of Biology and Entomology, The Pennsylvania State University, University Park, PA, 16802, USA.
Amir SheikhiDepartment of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA.ORCID 0000-0002-4495-6675

Funding

Applied Evolution Seed Grant from Penn State's College of AgricultureDorothy Foehr Huck and J. Lloyd Huck Early Career ChairEberly Chair of BiotechnologyPatricia and Stephen Benkovic Research Initiative
6 · The paper itself

Abstract

Vancomycin (VAN) and daptomycin (DAP) are among the last-resort antibiotics for treating multidrug-resistant Gram-positive bacterial infections. They are administered intravenously (IV); however, ≈5 - 10% of the total IV dose is released in the gastrointestinal (GI) tract via biliary excretion, driving resistance emergence in commensal Enterococcus faecium (E. faecium) populations. Here, it is reported that sevelamer (SEV), a Food and Drug Administration (FDA)-approved anion-exchange polymeric microparticle, captures anionic DAP within minutes and cationic VAN within hours, inactivating the antibacterial efficacy of DAP and VAN. In vitro SEV-mediated VAN or DAP transient removal is successfully described by a diffusion-adsorption mechanism. In vivo oral SEV treatment effectively prevented VAN resistance enrichment following the VAN treatment of E. faecium-colonized mice. This work shows, for the first time, that the adjuvant SEV therapy prevents antimicrobial resistance in nosocomial pathogens by eliminating off-target antibiotics. It is envisioned that SEV may protect DAP and VAN from resistance development, potentially addressing the long-lasting antimicrobial resistance.

Indexed as

Anti-Bacterial AgentsDrug Resistance, MicrobialPolymersAnimalsDaptomycinEnterococcus faeciumMiceMicrobial Sensitivity TestsVancomycinAnti-Bacterial AgentsDaptomycinPolymersVancomycinanti‐antibioticsantibiotic stewardshipantimicrobial resistancedaptomycinion exchange resinsvancomycin

Identifiers

PMID39828608
PMCPMC12105463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.